|
May 26, 2023 |
May 24, 2023 |
S
Sale
|
MORTIMER IAN
PRESIDENT & CEO
Executive Director
|
1,407
-4.3%
41.49
58,376
USD
|
1,407
-4.3%
|
41.49
|
58,376
USD
|
|
|
May 26, 2023 |
May 24, 2023 |
S
Sale
|
MORTIMER IAN
PRESIDENT & CEO
Executive Director
|
13,179
-32.2%
41.37
545,215
USD
|
13,179
-32.2%
|
41.37
|
545,215
USD
|
|
|
May 26, 2023 |
May 24, 2023 |
S
Sale
|
MORTIMER IAN
PRESIDENT & CEO
Executive Director
|
17,069
-41.3%
41.44
707,339
USD
|
17,069
-41.3%
|
41.44
|
707,339
USD
|
|
|
March 24, 2023 |
March 24, 2023 |
S
Sale
|
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
Officer
|
700
-100.0%
35.01
24,507
USD
|
700
-100.0%
|
35.01
|
24,507
USD
|
|
|
March 9, 2023 |
March 7, 2023 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
8,242
-13.0%
36.94
304,459
USD
|
8,242
-13.0%
|
36.94
|
304,459
USD
|
|
|
March 9, 2023 |
March 7, 2023 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
10,990
-24.4%
37.01
406,740
USD
|
10,990
-24.4%
|
37.01
|
406,740
USD
|
|
|
Nov. 28, 2022 |
Nov. 25, 2022 |
S
Sale
|
PATOU GARY
Non-Executive Director
|
1,937
-7.6%
34.79
67,390
USD
|
1,937
-7.6%
|
34.79
|
67,390
USD
|
|
|
Nov. 28, 2022 |
Nov. 23, 2022 |
S
Sale
|
PATOU GARY
Non-Executive Director
|
2,057
-8.0%
34.33
70,610
USD
|
2,057
-8.0%
|
34.33
|
70,610
USD
|
|
|
Sept. 7, 2022 |
Sept. 2, 2022 |
S
Sale
|
AULIN SHERRY
Chief Financial Officer
Officer
|
15,355
-100.0%
39.57
607,597
USD
|
15,355
-100.0%
|
39.57
|
607,597
USD
|
|
|
Sept. 2, 2022 |
Sept. 1, 2022 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
8,776
-34.3%
38.80
340,509
USD
|
8,776
-34.3%
|
38.80
|
340,509
USD
|
|
|
Sept. 2, 2022 |
Sept. 1, 2022 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
35,103
-57.9%
38.03
1,334,967
USD
|
35,103
-57.9%
|
38.03
|
1,334,967
USD
|
|
|
Sept. 2, 2022 |
Aug. 31, 2022 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
21,352
-56.0%
38.57
823,547
USD
|
21,352
-56.0%
|
38.57
|
823,547
USD
|
|
|
Aug. 16, 2022 |
Aug. 16, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
20,000
-76.9%
38.87
777,400
USD
|
20,000
-76.9%
|
38.87
|
777,400
USD
|
|
|
Aug. 16, 2022 |
Aug. 16, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
32,058
-55.2%
38.29
1,227,501
USD
|
32,058
-55.2%
|
38.29
|
1,227,501
USD
|
|
|
Aug. 16, 2022 |
Aug. 15, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
33,942
-36.9%
37.76
1,281,650
USD
|
33,942
-36.9%
|
37.76
|
1,281,650
USD
|
|
|
Aug. 16, 2022 |
Aug. 12, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
1,000
-1.1%
39.15
39,150
USD
|
1,000
-1.1%
|
39.15
|
39,150
USD
|
|
|
Aug. 16, 2022 |
Aug. 12, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
47,000
-33.6%
38.60
1,814,200
USD
|
47,000
-33.6%
|
38.60
|
1,814,200
USD
|
|
|
Aug. 16, 2022 |
Aug. 12, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
43,135
-23.6%
37.91
1,635,248
USD
|
43,135
-23.6%
|
37.91
|
1,635,248
USD
|
|
|
Aug. 16, 2022 |
Aug. 12, 2022 |
S
Sale
|
EMPFIELD JAMES R.
EVP, Drug Discovery
Officer
|
21,875
-68.6%
38.68
846,125
USD
|
21,875
-68.6%
|
38.68
|
846,125
USD
|
|
|
Aug. 16, 2022 |
Aug. 12, 2022 |
S
Sale
|
EMPFIELD JAMES R.
EVP, Drug Discovery
Officer
|
35,868
-52.9%
38.08
1,365,853
USD
|
35,868
-52.9%
|
38.08
|
1,365,853
USD
|
|
|
March 8, 2022 |
March 8, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
2,500
-1.3%
30.50
76,250
USD
|
2,500
-1.3%
|
30.50
|
76,250
USD
|
|
|
March 8, 2022 |
March 8, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
2,500
-1.3%
30.55
76,375
USD
|
2,500
-1.3%
|
30.55
|
76,375
USD
|
|
|
March 8, 2022 |
March 8, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
2,500
-1.3%
30.20
75,500
USD
|
2,500
-1.3%
|
30.20
|
75,500
USD
|
|
|
March 8, 2022 |
March 8, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
2,500
-1.3%
30.10
75,250
USD
|
2,500
-1.3%
|
30.10
|
75,250
USD
|
|
|
March 8, 2022 |
March 8, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
2,500
-1.3%
3.80
9,500
USD
|
2,500
-1.3%
|
3.80
|
9,500
USD
|
|
|
March 8, 2022 |
March 8, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
2,051
-1.0%
30.60
62,761
USD
|
2,051
-1.0%
|
30.60
|
62,761
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
EMPFIELD JAMES R.
EVP, Drug Discovery
Officer
|
31,048
-75.6%
30.54
948,206
USD
|
31,048
-75.6%
|
30.54
|
948,206
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
EMPFIELD JAMES R.
EVP, Drug Discovery
Officer
|
1,805
-4.2%
30.62
55,269
USD
|
1,805
-4.2%
|
30.62
|
55,269
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
2,500
-1.2%
30.55
76,375
USD
|
2,500
-1.2%
|
30.55
|
76,375
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
7,500
-3.6%
30.50
228,750
USD
|
7,500
-3.6%
|
30.50
|
228,750
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
2,500
-1.2%
30.52
76,300
USD
|
2,500
-1.2%
|
30.52
|
76,300
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
4,516
-2.1%
30.44
137,467
USD
|
4,516
-2.1%
|
30.44
|
137,467
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
4,516
-2.1%
30.45
137,512
USD
|
4,516
-2.1%
|
30.45
|
137,512
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
4,517
-2.0%
30.49
137,723
USD
|
4,517
-2.0%
|
30.49
|
137,723
USD
|
|
|
March 8, 2022 |
March 7, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
5,037
-2.2%
30.60
154,132
USD
|
5,037
-2.2%
|
30.60
|
154,132
USD
|
|
|
March 8, 2022 |
March 4, 2022 |
S
Sale
|
EMPFIELD JAMES R.
EVP, Drug Discovery
Officer
|
18,315
-64.7%
30.79
563,919
USD
|
18,315
-64.7%
|
30.79
|
563,919
USD
|
|
|
March 8, 2022 |
March 4, 2022 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
5,000
-22.5%
30.23
151,150
USD
|
5,000
-22.5%
|
30.23
|
151,150
USD
|
|
|
March 8, 2022 |
March 4, 2022 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
5,000
-18.4%
31.05
155,250
USD
|
5,000
-18.4%
|
31.05
|
155,250
USD
|
|
|
March 8, 2022 |
March 4, 2022 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
5,000
-15.5%
30.15
150,750
USD
|
5,000
-15.5%
|
30.15
|
150,750
USD
|
|
|
March 8, 2022 |
March 4, 2022 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
6,710
-17.2%
30.56
205,058
USD
|
6,710
-17.2%
|
30.56
|
205,058
USD
|
|
|
March 8, 2022 |
March 4, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
4,793
-2.2%
30.56
146,474
USD
|
4,793
-2.2%
|
30.56
|
146,474
USD
|
|
|
March 8, 2022 |
March 4, 2022 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
4,532
-2.1%
30.66
138,951
USD
|
4,532
-2.1%
|
30.66
|
138,951
USD
|
|
|
Jan. 21, 2022 |
Jan. 21, 2022 |
B
Purchase
|
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
Officer
|
700
+inf%
28.81
20,167
USD
|
700
+inf%
|
28.81
|
20,167
USD
|
|
|
Dec. 7, 2021 |
Dec. 6, 2021 |
B
Purchase
|
Von Seggern Christopher
Chief Commercial Officer
Officer
|
4,000
+inf%
24.40
97,600
USD
|
4,000
+inf%
|
24.40
|
97,600
USD
|
|
|
Nov. 16, 2021 |
Nov. 15, 2021 |
S
Sale
|
PIMSTONE SIMON N.
Non-Executive Director
|
17,557
-7.7%
31.33
550,061
USD
|
17,557
-7.7%
|
31.33
|
550,061
USD
|
|
|
June 1, 2021 |
May 28, 2021 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
2,912
-8.3%
18.81
54,775
USD
|
2,912
-8.3%
|
18.81
|
54,775
USD
|
|
|
June 1, 2021 |
May 28, 2021 |
S
Sale
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Officer
|
3,155
-8.2%
18.81
59,346
USD
|
3,155
-8.2%
|
18.81
|
59,346
USD
|
|
|
June 1, 2021 |
May 27, 2021 |
S
Sale
|
HOLLER FRANK A
Non-Executive Director
|
8,485
-5.6%
18.68
158,500
USD
|
8,485
-5.6%
|
18.68
|
158,500
USD
|
|
|
June 1, 2021 |
May 27, 2021 |
S
Sale
|
HOLLER FRANK A
Non-Executive Director
|
2,579
-1.7%
18.69
48,202
USD
|
2,579
-1.7%
|
18.69
|
48,202
USD
|
|
|
June 2, 2020 |
June 1, 2020 |
S
Sale
|
PIMSTONE SIMON N.
CEO
Executive Director
|
3,000
-1.2%
14.43
43,290
USD
|
3,000
-1.2%
|
14.43
|
43,290
USD
|
|
|
June 2, 2020 |
May 29, 2020 |
S
Sale
|
PIMSTONE SIMON N.
CEO
Executive Director
|
5,000
-1.9%
13.99
69,950
USD
|
5,000
-1.9%
|
13.99
|
69,950
USD
|
|
|
Sept. 24, 2019 |
Sept. 20, 2019 |
S
Sale
|
PIMSTONE SIMON N.
CEO
Executive Director
|
10,395
-3.9%
9.51
98,856
USD
|
10,395
-3.9%
|
9.51
|
98,856
USD
|
|
|
Sept. 20, 2019 |
Sept. 20, 2019 |
S
Sale
|
HOLLER FRANK A
|
5,206
-4.2%
9.39
48,884
USD
|
5,206
-4.2%
|
9.39
|
48,884
USD
|
|
|
Sept. 20, 2019 |
Sept. 19, 2019 |
S
Sale
|
HOLLER FRANK A
|
7,600
-5.8%
9.27
70,452
USD
|
7,600
-5.8%
|
9.27
|
70,452
USD
|
|
|
Sept. 18, 2019 |
Sept. 18, 2019 |
S
Sale
|
HOLLER FRANK A
|
4,368
-3.2%
9.28
40,535
USD
|
4,368
-3.2%
|
9.28
|
40,535
USD
|
|
|
Sept. 18, 2019 |
Sept. 17, 2019 |
S
Sale
|
HOLLER FRANK A
|
5,069
-3.6%
9.32
47,243
USD
|
5,069
-3.6%
|
9.32
|
47,243
USD
|
|
|
Sept. 17, 2019 |
Sept. 13, 2019 |
S
Sale
|
AZAB MOHAMMAD
|
23
-0.0%
9.31
214
USD
|
23
-0.0%
|
9.31
|
214
USD
|
|
|
Nov. 16, 2017 |
Nov. 15, 2017 |
B
Purchase
|
AZAB MOHAMMAD
|
15,000
+51.4%
2.22
33,281
USD
|
15,000
+51.4%
|
2.22
|
33,281
USD
|
|
|
Sept. 25, 2017 |
Sept. 22, 2017 |
B
Purchase
|
AZAB MOHAMMAD
|
8,000
+37.7%
2.95
23,600
USD
|
8,000
+37.7%
|
2.95
|
23,600
USD
|
|
|
Sept. 25, 2017 |
Sept. 21, 2017 |
B
Purchase
|
AZAB MOHAMMAD
|
2,000
+10.4%
2.95
5,900
USD
|
2,000
+10.4%
|
2.95
|
5,900
USD
|
|
|
Aug. 21, 2017 |
Aug. 18, 2017 |
B
Purchase
|
WINQUIST RAYMOND
Head, Translational Research
|
1,000
+inf%
3.00
2,995
USD
|
1,000
+inf%
|
3.00
|
2,995
USD
|
|
|
Aug. 21, 2017 |
Aug. 18, 2017 |
B
Purchase
|
AZAB MOHAMMAD
|
6,312
+48.9%
2.90
18,302
USD
|
6,312
+48.9%
|
2.90
|
18,302
USD
|
|
|
Aug. 21, 2017 |
Aug. 17, 2017 |
B
Purchase
|
AZAB MOHAMMAD
|
23
+0.2%
2.65
61
USD
|
23
+0.2%
|
2.65
|
61
USD
|
|
|
Aug. 17, 2017 |
Aug. 15, 2017 |
B
Purchase
|
EMPFIELD JAMES R.
SVP, Drug Discovery
|
10,000
+inf%
2.48
24,824
USD
|
10,000
+inf%
|
2.48
|
24,824
USD
|
|
|
Aug. 16, 2017 |
Aug. 15, 2017 |
B
Purchase
|
BVF PARTNERS L P/IL
Major owner
|
7,429
+0.7%
2.41
17,920
USD
|
7,429
+0.7%
|
2.41
|
17,920
USD
|
|
|
Aug. 16, 2017 |
Aug. 15, 2017 |
B
Purchase
|
BVF PARTNERS L P/IL
Major owner
|
11,429
+0.7%
2.41
27,569
USD
|
11,429
+0.7%
|
2.41
|
27,569
USD
|
|
|
Aug. 16, 2017 |
Aug. 14, 2017 |
B
Purchase
|
BVF PARTNERS L P/IL
Major owner
|
13,337
+1.3%
2.70
36,058
USD
|
13,337
+1.3%
|
2.70
|
36,058
USD
|
|
|
Aug. 16, 2017 |
Aug. 14, 2017 |
B
Purchase
|
BVF PARTNERS L P/IL
Major owner
|
28,007
+1.7%
2.70
75,720
USD
|
28,007
+1.7%
|
2.70
|
75,720
USD
|
|
|
Aug. 15, 2017 |
Aug. 14, 2017 |
B
Purchase
|
Svoronos Dawn
|
50,000
+inf%
2.82
140,770
USD
|
50,000
+inf%
|
2.82
|
140,770
USD
|
|
|
Aug. 14, 2017 |
Aug. 14, 2017 |
B
Purchase
|
Hayden Michael R
|
15,000
+10.3%
2.75
41,247
USD
|
15,000
+10.3%
|
2.75
|
41,247
USD
|
|
|
Aug. 14, 2017 |
Aug. 11, 2017 |
B
Purchase
|
GANNON STEVEN
|
15,000
+inf%
2.82
42,267
USD
|
15,000
+inf%
|
2.82
|
42,267
USD
|
|
|
Aug. 14, 2017 |
Aug. 10, 2017 |
B
Purchase
|
MORTIMER IAN
CFO & COO
|
10,000
+232.6%
2.90
29,000
USD
|
10,000
+232.6%
|
2.90
|
29,000
USD
|
|
|
Aug. 14, 2017 |
Aug. 10, 2017 |
B
Purchase
|
MORTIMER IAN
CFO & COO
|
5,000
+500.0%
2.85
14,225
USD
|
5,000
+500.0%
|
2.85
|
14,225
USD
|
|
|
Aug. 14, 2017 |
Aug. 10, 2017 |
B
Purchase
|
SCHELLER RICHARD H
|
7,000
+inf%
2.85
19,950
USD
|
7,000
+inf%
|
2.85
|
19,950
USD
|
|
|
Aug. 14, 2017 |
Aug. 10, 2017 |
B
Purchase
|
PATOU GARY
|
7,500
+150.0%
2.78
20,836
USD
|
7,500
+150.0%
|
2.78
|
20,836
USD
|
|
